Retrospective review of Acquired Haemophilia A from the largest Canadian Haemophilia treatment centre
Jai P. Jayakar
Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorNatalya O'Neill
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorMarie Yan
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorRosane Nisenbaum
Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, St Michael's Hospital, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorMarie B. Garvey
Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorJerome Teitel
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorCorresponding Author
Michelle Sholzberg
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Correspondence: Michelle Sholzberg, St Michael's Hospital, Room 2-007G Core Lab, Cardinal Carter Wing, 30 Bond Street, Toronto ON M5B 1W8, Canada ([email protected]).Search for more papers by this authorJai P. Jayakar
Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorNatalya O'Neill
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorMarie Yan
Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorRosane Nisenbaum
Centre for Research on Inner City Health, Li Ka Shing Knowledge Institute, St Michael's Hospital, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorMarie B. Garvey
Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorJerome Teitel
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Search for more papers by this authorCorresponding Author
Michelle Sholzberg
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
Correspondence: Michelle Sholzberg, St Michael's Hospital, Room 2-007G Core Lab, Cardinal Carter Wing, 30 Bond Street, Toronto ON M5B 1W8, Canada ([email protected]).Search for more papers by this author
References
- 1Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. Semin Thromb Hemost. 2014; 40: 803-811.
- 2Baudo F, de Cataldo F. The problem of acquired hemophilia. Blood. 2015; 125: 1052-1053.
- 3Baudo F, Collins P, Huth-Kuehne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012; 120: 39-46.
- 4Collins PW. Management of acquired haemophilia A. J Thromb Haemost. 2011; 9: 226-235.
- 5Tiede A, Scharf R, Dobbelstein C, Werwitzke S. Management of acquired haemophilia A. Hämostaseologie. 2015; 35: 311-318.
- 6Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012; 120: 47-55.
- 7Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012; 10: 622-631.
- 8Tengborn L, Baudo F, Huth-Kühne A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG. 2012; 119: 1529-1537.
- 9Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015; 125: 1091-1097.
- 10Tiede A, Hofbauer CJ, Werwitzke S, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 Study. Blood. 2016; 127: 2289-2297.
- 11Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3: 692-694. https://doi.org/10.1111/j.1538-7836.2005.01204.x.
- 12Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121: 21-35.
- 13Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007; 109: 1870-1877.
- 14 NovoNordisk-Canada. NiaStase RT (activated recombinant factor VIIa) product monograph. 2015. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/niastase-product-monograph.pdf. Accessed June 2017.
- 15 Baxter-Healthcare-Corporation. FEIBA NF product monograph. 2011. http://www.feiba.com/us/forms/feiba_nf_pi.pdf. Accessed June 2017.
Citing Literature
